{
    "2021-04-27": [
        [
            {
                "time": "",
                "original_text": "西南证券给予华大基因持有评级，新冠检测需求驱动2020年业绩大增，常规业务逐步恢复",
                "features": {
                    "keywords": [
                        "华大基因",
                        "新冠检测",
                        "业绩大增",
                        "常规业务恢复"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "西南证券：华大基因（300676.SZ）新冠检测需求驱动2020年业绩大增，维持“持有”评级",
                "features": {
                    "keywords": [
                        "华大基因",
                        "新冠检测",
                        "业绩大增",
                        "持有评级"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "电鳗快报|福兮祸所依！华大基因年报净利润激增6倍 多项费用及信用减值损失也同步大增",
                "features": {
                    "keywords": [
                        "华大基因",
                        "净利润激增",
                        "费用增加",
                        "信用减值损失"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "mixed",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}